Please replace the release due to revisions to the company boilerplate.
The corrected release reads:
OPTINOSE TO PRESENT AT THE 35th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
OptiNose today announced that the company will present at the 35th annual J.P. Morgan Healthcare Conference. CEO Peter Miller will discuss the Company's recent milestones, pipeline and plans for 2017.
“We are excited to have the opportunity to update the investment community on recent company milestones, our impressive late stage pipeline and business strategy as we enter 2017,” Miller stated.
Miller will present on Monday, January 9, 2017 at 12:00 p.m. in the Elizabethan C/D room at the Westin St. Francis Hotel in San Francisco.
OptiNose is a commercial stage ENT / Allergy Specialty Biopharmaceutical Company on a mission to improve patient lives. The Company’s patented closed-palate Breath Powered® technology is a platform for developing novel treatments that are aimed at creating meaningful benefits with high and deep intranasal deposition of medication. OptiNose developed and out-licensed a first product at the end of phase 3 (Onzetra™ Xsail™, licensed to Avanir in North America, since acquired by Otsuka Pharmaceutical Co) which received FDA approval in January 2016 and was launched in May 2016. OptiNose is also in late stage development of an Exhalation Delivery System for fluticasone (OPN-375) for patients with chronic nasal inflammatory diseases, and has completed Phase 3 investigational studies in patients with chronic rhinosinusitis and nasal polyps. Other OptiNose pipeline products also target large markets with significant unmet need, including nose-to-brain technology applications such as OPN-300 for Autism. OptiNose has corporate offices in the US, Norway and the UK.
Forward Looking Statements
This press release may contain forward looking statements. Forward looking statements include statements about our future plans and may be indicated by words such as, “we expect,” “we plan,” or other similar words. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. We are not obligating ourselves to revise or publicly release the results of any revision to these forward looking statements in light of new information or future events.
Sloane & Company
Kate Traynor, 212-446-1871